I don't think that the FDA has given Pluristem full approval to commercialize any of their products, only the green light to move forward with testing. They do have a market cap nearly $110 million. And have benefited from around $15 million in grants and a partnership with Charité medical school in Berlin. Perhaps by funding through grants and partnerships they've been able to avoid the pitfalls of stock dilution and high interest loans to keep operations moving forward.
I hope that USRM gains FDA approval for commercialization and soon surpasses Pluristem's market cap.
News 
Market Data 
Discover 
